Enu Pharma Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$2.55M
- Investors
-
6
Enu Pharma General Information
Description
Developer of a nanosome technology designed to help doctors easily cure intractable diseases. The company's technology is made of core metals covered by an antiadhesive mixed self-assembled monolayer to avoid non-specific surface protein corona, enabling medical professionals to unlock the potential of drug discovery, development, and delivery.
Contact Information
Website
www.enupharma.comCorporate Office
- International Center for Food & Medical Innovation
- 1st floor, HX, Kita 21-jo Nishi 11-chome, Kita-ku
- Sapporo, Hokkaido 001-0021
- Japan
Corporate Office
- International Center for Food & Medical Innovation
- 1st floor, HX, Kita 21-jo Nishi 11-chome, Kita-ku
- Sapporo, Hokkaido 001-0021
- Japan
Enu Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Seed Round | 31-Jan-2025 | $2.55M | Completed | Generating Revenue | ||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Enu Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Enu Pharma Patents
Enu Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025142818-A1 | Fusion protein, conjugate, and application for same | Inactive | 27-Dec-2023 | ||
| EP-4741412-A1 | Glycopeptide, method for analyzing glycopeptide, and method for analyzing cancer | Pending | 05-Jul-2023 | ||
| WO-2025009551-A1 | Glycopeptide, method for analyzing glycopeptide, and method for analyzing cancer | Inactive | 05-Jul-2023 | ||
| EP-4722227-A1 | Complex, pharmaceutical composition, vaccine, and applications thereof | Pending | 25-May-2023 | ||
| WO-2024241964-A1 | Complex, pharmaceutical composition, vaccine, and applications thereof | Inactive | 25-May-2023 | A61P35/00 |
Enu Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Enu Pharma Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DG Ventures | Corporate Venture Capital | Minority | ||
| Kyoto University Innovation Capital | Venture Capital | Minority | ||
| Startup Hokkaido | Accelerator/Incubator | Minority | ||
| Taiho Innovations | Corporate Venture Capital | Minority | ||
| FASTAR | Accelerator/Incubator |
Enu Pharma FAQs
-
When was Enu Pharma founded?
Enu Pharma was founded in 2019.
-
Where is Enu Pharma headquartered?
Enu Pharma is headquartered in Sapporo, Japan.
-
What is the size of Enu Pharma?
Enu Pharma has 10 total employees.
-
What industry is Enu Pharma in?
Enu Pharma’s primary industry is Drug Delivery.
-
Is Enu Pharma a private or public company?
Enu Pharma is a Private company.
-
What is Enu Pharma’s current revenue?
The current revenue for Enu Pharma is .
-
How much funding has Enu Pharma raised over time?
Enu Pharma has raised $2.55M.
-
Who are Enu Pharma’s investors?
DG Ventures, Kyoto University Innovation Capital, Startup Hokkaido, Taiho Innovations, and FASTAR are 5 of 6 investors who have invested in Enu Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
